Health Programs
NeuTigers' portfolio of disease-specific Edge-AI programs, organized by evidence maturity — from research to partner-ready — with a clearly stated status for each.
A portfolio organized by evidence
The portfolio is anchored on the metabolic-risk continuum: SweetDeep™, our flagship program for non-invasive type 2 diabetes risk screening on everyday wearables, and MFDeep, the women's-health pillar addressing fetal macrosomia risk in gestational diabetes. Around that core sit broader high-unmet-need programs — sickle cell disease and mental health — and the StarDeep™ Agentic AI Platform that runs the decentralized clinical trials behind them. Each program packages StarDeep-built models into a disease-specific solution: a defined indication, a defined data source (typically wearable or connected-device signals), and a defined stage of evidence. We organize the portfolio by evidence maturity so partners can see at a glance what each program is — and what it is not yet.
What the status labels mean
- Research — early-stage scientific work: proofs of concept, exploratory studies, published methods. Not a product.
- Retrospective validation — model performance has been evaluated on previously collected datasets, typically reported in a publication.
- Prospective study — the program is being, or has been, evaluated in a forward-looking study with a clinical partner, collecting real-world data under a defined protocol.
- Clinical validation — performance has been confirmed in clinical studies designed to support real-world use with partners.
- Partner-ready — the program is mature enough for structured partner engagements such as co-development, sponsored validation or integration.
No status label implies regulatory clearance, approval or diagnostic status in any jurisdiction. Programs are made available to partners for development and validation collaborations at the stage indicated. Questions about a specific program's evidence? See the evidence library or contact us.
| Program | Indication | Data source | Status | Partnership |
|---|---|---|---|---|
| SweetDeep | Wearable-AI diabetes risk screening | Multi-sensor wearables (ECG, PPG, BP, BIA, SpO2, skin temperature, motion, activity, sleep) + lifestyle questionnaire | Clinically validated — 4 studies, 3 continents | Ready for strategic pilots and commercial discussions — wellness launch path with Samsung; clinical expansion path with pharma/medical device partners |
| MFDeep | Fetal macrosomia prediction — women's health | Maternal clinical data, biochemical markers and ultrasound biometry, with on-device real-time inference | Active clinical development | In active development with French clinical partners; open to additional partners |
| StarDeep™ Agentic AI Platform | Decentralized clinical trials (DCTs) | Fleet of connected devices (CGMs, smartwatches, phones) and apps | In development | Open to sponsors, CROs and clinical sites for pilot studies |
| Sickle Cell Program | Vaso-occlusive crisis prevention in sickle cell disease | Everyday wearables (e.g., Withings ScanWatch) | Clinical research | Seeking clinical and funding partners to advance validation |
| MHDeep | Mental health disorder monitoring and detection | Smartwatch and smartphone sensor data | Research | Seeking research and clinical partners |
| CovidDeep | COVID-19 detection | Smartwatch sensors and questionnaire data | Published research (historical) | Historical program; methods available through platform licensing |